NCT02240433 - A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC) | Biotech Hunter

Enrollment

9

Participants

Timeline

Start Date

November 12, 2014

Primary Completion Date

July 19, 2017

Study Completion Date

December 25, 2019

Conditions

Hepatocellular Carcinoma

Interventions

DRUG

LY2157299

LY2157299 administered orally

DRUG

Sorafenib

Sorafenib administered orally

Trial Locations (3)

277 8577

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chiba

241-8515

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kanagawa

565-0871

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Suita-shi